Metabonomics technology and its applications in disease diagnosis

Abstract

CLC Number:

R969.1

GUAN En-ze, ZHU Xuan-xuan, WANG Guang-ji, HAO Hai-ping, DING Yang. Metabonomics technology and its applications in disease diagnosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 11-15.

References

[1] Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research[J]. Nature, 2003, 422(6934):835-847.
[2] John R. Metabolomics-an important emerging science. Business briefing: pharmatech[J]. Drug Discov Today, 2004, 1: 51-54.
[3] Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics[J] ? Anal Chem, 2003, 75(17):384A-391A.
[4] Nicholson JK, Wilson ID. Understanding global systems biology: metabonomics and the continuum of metabolism[J]. Nat Rev Drug Discover, 2003, 2(8):668-676.
[5] Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network[J]. Science, 2001, 292(5518):929-934.
[6] Oliver SG, Winson MK, Kell DB, et al. Systematic functional analysis of the yeast genome[J]. Trends Biotechnel, 1998, 16(9):373.
[7] Oliver SG. Yeast as an avigational tool in genome analysis[J]. Microbiology, 1997, 143(2):1483-1487.
[8] Nicholson JK, Lindon JC, Holmes E. Metabonomics:understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11):1181-1189.
[9] Fiehn O, Kopka J, Dormann P, et al. Metabolite profiling for plant functional genomics[J]. Nat Biotechnol, 2000, 18(11):1157-1161.
[10] Schmidt CW. Metabolomics:what's happening downstream of DNA[J]. Environ Health Perspect, 2004, 112(7):A410.
[11] Griffin JL, Walker LA, Garrod S, et al. NMR spectroscopy based metabonomic studies on the comparative biochemistry of the kidney and urine of the bank vole (Clethrionomys glareolus), wood mouse (Apodemus sylvaticus), white toothed shrew (Crocidura suaveolens)and the laboratory rat[J]. Comp Biochem Phy siol B Biochem Mol Biol, 2000, 127(3):357-367.
[12] Huhn SD, Szabo CM, Gass JH, et al. Metabolic profiling of normal and hypertensive rat kidney tissues by hrMAS-NMR spectroscopy[J]. Anal Bioanal Chem, 2004, 378(6):1511-1519.
[13] Taylor J, King RD, Altmann T, et al. Application of metabolomics to plant genotype discrimination using statistics and machine learning[J]. Bioinformatics, 2002, 18(3):241-248.
[14] Plumb RS, Stumpf CL, Granger JH, et al. Use of liquid chromatography time-of-flight masss pectrom etry and multivariate statisticalan alysis shows promise for the detection of drug metabolites in biological fluids[J]. Rapid Commun Mass Spectrom, 2003, 17(23):2632-2638.
[15] Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring drug safety assessment and disease diagnosis[J]. Biomarkers, 2004, 9(1):1-31.
[16] Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics[J]. Nat Med, 2002, 8(12):1439-1444.
[17] Sabatine MS, Liu E,Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia[J]. Circulation, 2005;112(25):3868-3875.
[18] Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease[J]. Proteome Res, 2007, 6(2):546-551.
[19] Yin P, Zhao X, Li Q, et al. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC Q-TOF MS)[J]. Proteome Res, 2006, 5(9):2135-2143.
[20] Yang J, Xu GW, Zheng YF, et al. Strategy for metabonomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry[J]. J Chromatogr A, 2005, 1084:214-221.
[21] Robertson DG, Reily MD, Sigler RE, et al. Metabonomics: evaluation of nuclear magnetic resonance (NMR)and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants[J]. Toxicol Sci, 2000, 57(2):326-337.
[22] Psihogios NG, Kalaitzidis RG, Dimou S, et al. Evaluation of Tubulointerstitial Lesions'Severity in Patients with Glomerulonephritides: An NMR-Based Metabonomic Study[J]. Proteome Res, 2007, 6(9):3760-3770.
[23] Holmes E, Connor SC, Nicholls AW, et al. The identification of novel biomark2ers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine[J]. Chemometri Intell Lab Sys, 1999, 44: 245-255.
[24] Mäkinen V P, Soininen P, Forsblom C, et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum[J]. MAGMA, 2006, 19(6):281-296.
[25] Yang J, Xu GW, Hong Q, et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles[J]. Chromatogr B Analyt Technol Biomed Life Sci, 2004, 813(1-2): 53-58.
[26] Yuan K, Kong H, Guan Y, et al. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile[J]. Chromatogr B Analyt Technol Biomed Life Sci, 2007, 850(1-2):236-240.
[27] Xu GW, Liebich H. Normal and modified nucleosides in urine as potential tumor markers determined by MEKC and HPLC[J]. Am Clin Lab, 2001 ;20:22-32.
[28] Yang J, Xu GW, Kong HW, et al. Artificial neural network classification based on high-performance liquid chromatography of urinary and serum nucleosides for the clinical diagnosis of cancer[J]. J Chro-matogr B, 2002, 780(1):27-33.
[29] Zheng YF, Xu GW, Liu DY, et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography[J]. Electrophoresis, 2002, 23(24):4104-4109.
[30] Hewer R, Vorster J, Steffens F E, et al. Applying biofluid1H NMR-based metabonomic techniques to distinguish between HIV-1 positive AIDS patients on antiretroviral treatment and HIV-1 negative individuals[J]. Pharm Biomed Anal, 2006, 41(4):1442-1446.